Cargando…
Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical r...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395392/ https://www.ncbi.nlm.nih.gov/pubmed/34436036 http://dx.doi.org/10.3390/curroncol28040270 |
_version_ | 1783744161148567552 |
---|---|
author | O’Sullivan, Dylan E. Cheung, Winson Y. Syed, Iqra A. Moldaver, Daniel Shanahan, Mary Kate Bebb, D. Gwyn Sit, Christina Brenner, Darren R. Boyne, Devon J. |
author_facet | O’Sullivan, Dylan E. Cheung, Winson Y. Syed, Iqra A. Moldaver, Daniel Shanahan, Mary Kate Bebb, D. Gwyn Sit, Christina Brenner, Darren R. Boyne, Devon J. |
author_sort | O’Sullivan, Dylan E. |
collection | PubMed |
description | The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical records and administrative claims data. In all, 1941 ES-SCLC patients were included, of which 476 (25%) were recurrent cases. Median age at diagnosis was 70 years (range: 39–94) and 50.2% were men. Of the 1941 ES-SCLC patients, 29.5% received chemotherapy and radiotherapy, 17.0% chemotherapy alone, 8.7% radiotherapy alone, and 44.8% received best supportive care. Chemotherapy was initiated by 46.5%, 8.5%, and 1.4% of first-, second-, and third-line patients, with lower uptake for recurrent cases. Median survival from first-, second-, and third-line chemotherapy was 7.82 months (95% CI: 7.50–8.22), 5.72 months (95% CI: 4.90–6.87), and 3.83 months (95% CI: 2.99–4.60). Among patients who received first-line therapy, the 2-year and 5-year survival was 7.3% (95% CI: 5.7–9.2) and 2.9% (95% CI: 1.8–4.5). In conclusion, initiation of first-line treatment in ES-SCLC was low with significant attrition in subsequent lines. These results underscore the need for effective front-line treatments and highlight the potential for novel therapies to improve patient outcomes. |
format | Online Article Text |
id | pubmed-8395392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83953922021-08-28 Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada O’Sullivan, Dylan E. Cheung, Winson Y. Syed, Iqra A. Moldaver, Daniel Shanahan, Mary Kate Bebb, D. Gwyn Sit, Christina Brenner, Darren R. Boyne, Devon J. Curr Oncol Article The prognosis for extensive-stage small cell lung cancer (ES-SCLC) is poor. Real-world evidence can highlight the unmet clinical need within this population. We conducted a population-based cohort study of ES-SCLC patients diagnosed in a large Canadian province (2010–2018) using electronic medical records and administrative claims data. In all, 1941 ES-SCLC patients were included, of which 476 (25%) were recurrent cases. Median age at diagnosis was 70 years (range: 39–94) and 50.2% were men. Of the 1941 ES-SCLC patients, 29.5% received chemotherapy and radiotherapy, 17.0% chemotherapy alone, 8.7% radiotherapy alone, and 44.8% received best supportive care. Chemotherapy was initiated by 46.5%, 8.5%, and 1.4% of first-, second-, and third-line patients, with lower uptake for recurrent cases. Median survival from first-, second-, and third-line chemotherapy was 7.82 months (95% CI: 7.50–8.22), 5.72 months (95% CI: 4.90–6.87), and 3.83 months (95% CI: 2.99–4.60). Among patients who received first-line therapy, the 2-year and 5-year survival was 7.3% (95% CI: 5.7–9.2) and 2.9% (95% CI: 1.8–4.5). In conclusion, initiation of first-line treatment in ES-SCLC was low with significant attrition in subsequent lines. These results underscore the need for effective front-line treatments and highlight the potential for novel therapies to improve patient outcomes. MDPI 2021-08-13 /pmc/articles/PMC8395392/ /pubmed/34436036 http://dx.doi.org/10.3390/curroncol28040270 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article O’Sullivan, Dylan E. Cheung, Winson Y. Syed, Iqra A. Moldaver, Daniel Shanahan, Mary Kate Bebb, D. Gwyn Sit, Christina Brenner, Darren R. Boyne, Devon J. Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title_full | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title_fullStr | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title_full_unstemmed | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title_short | Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada |
title_sort | real-world treatment patterns, clinical outcomes, and health care resource utilization in extensive-stage small cell lung cancer in canada |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395392/ https://www.ncbi.nlm.nih.gov/pubmed/34436036 http://dx.doi.org/10.3390/curroncol28040270 |
work_keys_str_mv | AT osullivandylane realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT cheungwinsony realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT syediqraa realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT moldaverdaniel realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT shanahanmarykate realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT bebbdgwyn realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT sitchristina realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT brennerdarrenr realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada AT boynedevonj realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinextensivestagesmallcelllungcancerincanada |